Literature DB >> 26646775

Refractive errors and ocular biometry components in thalassemia major patients.

Samira Heydarian1, Reza Jafari2, Hosein Karami3.   

Abstract

The aim of this study is to determine and compare biometric and refractive characteristics of thalassemia major patients and normal individuals. In this cross-sectional study, 54 thalassemia major patients were selected randomly as case group, and 54 age- and sex-matched healthy subjects were regarded as control group. Refractive errors, corneal curvature and ocular components were measured by autokeratorefractometery and A-scan ultrasonography, respectively. Mean spherical equivalent was -0.0093 ± 0.86 D in thalassemia patients and -0.22 ± 1.33 D in the normal group. The prevalence of myopia, Hyperopia, and emmetropia among thalassemia patients was 16.7, 19.4, and 63.9 %, respectively. While in the control group, 26.9 % were myopic, 25 % were hyperopic, and 48.1 % were emmetropic. The prevalence of astigmatism in case group was 22.2 %, which was not significantly different from that in control group, (27.8 %, p = 0.346). Mean axial length in thalassemia patients was 22.89 ± 0.70 which was significantly lower than that in normal group (23.37 ± 0.91, p = 0.000). The flattest meridian of the cornea (R1) was significantly steeper in thalassemia patients (7.77 ± 0.24) in comparison to normal individuals (7.85 ± 0.28). Although thalassemic patients had significantly smaller axial length and vitreous chamber depth in comparison to normal group, which could be due to their abnormal physical growth, there was no significant difference between the mean of spherical equivalent among two groups. This can be due to their steeper corneal curvature that overcomes the refractive disadvantage of their shorter axial length.

Entities:  

Keywords:  Axial length; Corneal curvature; Ocular biometry; Refractive error; Thalassemia major

Mesh:

Year:  2015        PMID: 26646775     DOI: 10.1007/s10792-015-0161-8

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  18 in total

1.  Rapidly progressing bilateral cataracts in a patient with beta thalassemia and pellagra.

Authors:  Ioannis Athanasiadis; Aristeidis Konstantinidis; Ioannis Kyprianou; Rosemary Robinson; Vaia Moschou; Kokkona Kouzi-Koliakos
Journal:  J Cataract Refract Surg       Date:  2007-09       Impact factor: 3.351

2.  [Internal astigmatism with other ocular lesions].

Authors:  R Limaiem; A Baba; R Bouraoui; F Mghaieth; L El Matri
Journal:  J Fr Ophtalmol       Date:  2012-03-17       Impact factor: 0.818

3.  HBED: A potential alternative to deferoxamine for iron-chelating therapy.

Authors:  R J Bergeron; J Wiegand; G M Brittenham
Journal:  Blood       Date:  1998-02-15       Impact factor: 22.113

4.  Ocular refractive and biometric characteristics in patients with thalassaemia major.

Authors:  Mohammad Hosein Nowroozzadeh; Zahra Kalantari; Khadije Namvar; Mohammad Hassan Meshkibaf
Journal:  Clin Exp Optom       Date:  2011-02-16       Impact factor: 2.742

5.  [The analysis of the axises of corneal astigmatism and total astigmatism in astigmatic patients].

Authors:  Z Dai; R Yu; X Gong; S Wang
Journal:  Yan Ke Xue Bao       Date:  2000-12

6.  Ocular abnormalities in patients with beta thalassemia on transfusion and chelation therapy: our experience.

Authors:  Jitendra Jethani; Kenshuk Marwah; Shashank Patel; Bela Shah
Journal:  Indian J Ophthalmol       Date:  2010 Sep-Oct       Impact factor: 1.848

7.  Survival in medically treated patients with homozygous beta-thalassemia.

Authors:  N F Olivieri; D G Nathan; J H MacMillan; A S Wayne; P P Liu; A McGee; M Martin; G Koren; A R Cohen
Journal:  N Engl J Med       Date:  1994-09-01       Impact factor: 91.245

Review 8.  New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia.

Authors:  Ersi Voskaridou; Evangelos Terpos
Journal:  Br J Haematol       Date:  2004-10       Impact factor: 6.998

9.  Premarital screening for beta-thalassaemia in Southern Iran: options for improving the programme.

Authors:  Mehran Karimi; Nima Jamalian; Hooman Yarmohammadi; Abdolrasoul Askarnejad; Abdolreza Afrasiabi; Alireza Hashemi
Journal:  J Med Screen       Date:  2007       Impact factor: 2.136

Review 10.  Beta-thalassemia.

Authors:  Antonio Cao; Renzo Galanello
Journal:  Genet Med       Date:  2010-02       Impact factor: 8.822

View more
  5 in total

Review 1.  Ocular abnormalities in beta thalassemia patients: prevalence, impact, and management strategies.

Authors:  Samira Heydarian; Reza Jafari; Kiumars Nowroozpoor Dailami; Hassan Hashemi; Ebrahim Jafarzadehpour; Mohsen Heirani; Abbasali Yekta; Monireh Mahjoob; Mehdi Khabazkhoob
Journal:  Int Ophthalmol       Date:  2019-10-10       Impact factor: 2.031

2.  Evaluation of serum levels in T3, T4 and TSH in beta-thalassemic patients referred to the Abuzar hospital in Ahwaz.

Authors:  Zari Tahannejad Asad; Majid Ghazanfari; Seyyed Nima Naleini; Azam Sabagh; Wesam Kooti
Journal:  Electron Physician       Date:  2016-07-25

3.  Ocular manifestations of sickle cell disease.

Authors:  Beuy Joob; Viroj Wiwanitkit
Journal:  Taiwan J Ophthalmol       Date:  2018 Jan-Mar

4.  Anterior Chamber Angle, Intraocular Pressure, and Globe Biometric Parameters in the Children with β-Thalassemia Major.

Authors:  Nermien Sm El-Haddad
Journal:  J Curr Glaucoma Pract       Date:  2020 Jan-Apr

5.  Ocular findings in patients with transfusion-dependent β-thalassemia in southern Iran.

Authors:  Sezaneh Haghpanah; Omid Reza Zekavat; Mohammadreza Bordbar; Mehran Karimi; Soheila Zareifar; Sanaz Safaei; Mani Ramzi; Hossein Ashraf
Journal:  BMC Ophthalmol       Date:  2020-09-22       Impact factor: 2.209

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.